Clinical trials: Endocrine Disorder
Fallopian Tube Cancer, Ovarian Cancer
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Ovarian Neoplasms, Ovary Cancer
- Trial name
- nCYT (NCT03593681)
- Testing
- Hysteroscopic cell sampling of the fallopian tube
- Where
- 10 sites in United States
- Volunteers
- 150 people
- Sponsor
- Boston Scientific Corporation
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens
This trial is conducted in Asia and North America. The aim of this trial is to compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily in insulin-naïve subjects with type 2 diabetes mellitus when…
- Trial name
- BOOST™ (NCT01365507)
- Testing
- insulin degludec/insulin aspart
- Where
- 42 sites in United States, Malaysia and 5 more
- Volunteers
- 276 people
- Sponsor
- Novo Nordisk A/S
Hypogonadism
A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy
The main purpose of this study is to evaluate if testosterone solution can raise testosterone hormone levels into the normal range, and also improve levels of sexual arousal, interest and drive and/or energy level, in men with…
- Trial name
- NCT01816295
- Testing
- Testosterone Solution
- Where
- 85 sites in United States, Argentina and 7 more
- Volunteers
- 715 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals
The diabetes technology group at Imperial College have developed a bio-inspired artificial pancreas (BiAP) system which uses a control algorithm based on a mathematical model of beta-cell physiology.
- Trial name
- NCT02397265
- Testing
- Bi-hormonal closed loop pump, Standard opened loop pump, Insulin closed loop
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Imperial College London
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Fast-acting insulin aspart (faster aspart) will be tested to see how well it works and if it is safe. The study compares 2 medicines for type 1 and type 2 diabetes - faster aspart (a new medicine) and insulin aspart (a medicine…
- Trial name
- NCT04588259
- Testing
- Faster aspart, Insulin aspart, Insulin degludec
- Where
- 40 sites in China, Hong Kong
- Volunteers
- 331 people
- Sponsor
- Novo Nordisk A/S
Fallopian Tube Cancer, Ovarian Cancer
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
RATIONALE: Monoclonal antibodies, such as Hu3S193, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00617773
- Testing
- hu3S193
- Where
- 8 sites in Brazil
- Volunteers
- 31 people
- Sponsor
- Recepta Biopharma
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
This study compares insulin icodec (a new insulin taken once a week) to insulin degludec (an insulin taken once daily which is already available on the market) in people with type 2 diabetes.
- Trial name
- ONWARDS 3 (NCT04795531)
- Testing
- Insulin icodec, Insulin degludec
- Where
- 190 sites in United States, Argentina and 10 more
- Volunteers
- 588 people
- Sponsor
- Novo Nordisk A/S
Sleep Apnea, Diabetes
Hyperglycemic Profiles in Obstructive Sleep Apnea: Effects of PAP Therapy
This is a randomized control trial in people with diabetes and obstructive sleep apnea who will be randomly assigned for 3 months to PAP therapy along with healthy lifestyle and sleep education or healthy lifestyle and sleep…
- Trial name
- HYPNOS (NCT02454153)
- Testing
- REMStar Positive Airway Pressure, LifeStyle Counseling
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Johns Hopkins University
Type 1 Diabetes Mellitus
Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System
The purpose of this study is to assess the efficacy of the Low Glucose Suspend (LGS) feature in reducing hypoglycemia with the MiniMed Paradigm® X54 System with hypoglycemic induction from exercise.
- Trial name
- NCT01148862
- Testing
- The MiniMed Paradigm® X54 System
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medtronic MiniMed, Inc.
Pancreatic Cancer
Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
The main purpose of this study is to look at the effectiveness, safety, and antitumor activity (preventing growth of the tumor) of the experimental study drug rucaparib (also known as CO-338) on subjects and on their pancreatic…
- Trial name
- NCT03140670
- Testing
- RUCAPARIB
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Depression, Fatigue
Programs To Support You During Chemotherapy
This randomized pilot trial studies how well two supportive programs work for improving fatigue and depressive symptoms in patients with GI undergoing chemotherapy.
- Conditions
- Depression, Fatigue, Stage IIA Colorectal Cancer, Stage IIB Colorectal Cancer
- Trial name
- PRO-YOU (NCT02489422)
- Testing
- Laboratory Biomarker Analysis, Questionnaire Administration, Daily Survey Administration
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Wake Forest University Health Sciences
Type 2 Diabetes Mellitus
Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin
This study is intended to assess the effect on HbA1c of different dose regimens of LX4211 in combination with metformin in subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT01376557
- Testing
- 75 mg LX4211, 200 mg LX4211, 400 mg LX4211
- Where
- 56 sites in United States
- Volunteers
- 299 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes
Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
The purpose of this study is to find out if treatment with degludec insulin when compared to glargine U100 insulin will result in similar blood sugar control in patients with diabetes who are admitted to the hospital and then…
- Trial name
- NCT03336528
- Testing
- Degludec, Glargine, Aspart
- Where
- 4 sites in United States
- Volunteers
- 180 people
- Sponsor
- Emory University
Congenital Adrenal Hyperplasia
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
This study is a randomized, double-blind, active-controlled, phase III study of Chronocort® compared with immediate-release hydrocortisone replacement therapy in participants aged 16 years and over with Congenital Adrenal…
- Trial name
- CONnECT (NCT05063994)
- Testing
- Chronocort, Cortef
- Where
- 21 sites in United States, France and 1 more
- Volunteers
- 55 people
- Sponsor
- Neurocrine UK Limited
Diabetes Mellitus, Type 1
ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)
This post-market, interventional, prospective, single arm, the United States (US) based multi-center study will assess the change in treatment satisfaction of participants who utilize the ACCU-CHEK Connect Diabetes Management…
- Trial name
- NCT02600845
- Testing
- ACCU-CHEK
- Where
- 11 sites in United States
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Bone Marrow Failure Syndrome, Thalassemia
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum…
- Conditions
- Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia
- Trial name
- NCT03513328
- Testing
- Thiotepa--single daily dose, Thiotepa--escalated dose
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Pancreatic Cancer
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic…
- Trial name
- NCT01688336
- Testing
- FOLFIRINOX
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Diabetic Foot Ulcer
Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)
The primary objective of this study is to determine the outcomes of patients who receive a certain type of skin substitute called RestrataTM Wound Matrix (Restrata™).
- Trial name
- NCT03312595
- Testing
- Restrata TM Wound Matrix
- Where
- 5 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Acera Surgical, Inc.
Type 1 Diabetes
Healthy And Positive Pathways for Young People With Type 1 Diabetes (HAPPY T1D)
In this 2-year randomized clinical trial, we will implement and assess the impact of a behavioral/psychoeducational intervention to reduce diabetes distress and improve glycemic outcomes in adolescents and young adults, aged…
- Trial name
- NCT05413239
- Testing
- Psychoeducation to reduce diabetes distress and improve glycemic outcomes
- Where
- 2 sites in United States
- Volunteers
- 217 people
- Sponsor
- Joslin Diabetes Center
Type 1 Diabetes Mellitus, Type2 Diabetes Mellitus
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT03966911
- Testing
- Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
- Where
- 15 sites in United States
- Volunteers
- 335 people
- Sponsor
- Medtronic MiniMed, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.